Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Bioasis Technologies Inc. BIOAF


Primary Symbol: V.BTI

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.

The Market Herald Price Sensitive
{{currentVideo.title}} {{currentVideo.relativeTime}}
{{currentVideo.storiesTitle}}:
{{story.companySymbol}}
{{story.companySymbol}} {{story.headline}}
< Previous bulletin
Next bulletin >
View modes: 

RE:RE:RE:RE:RE:A Little STFU Story

Wow! What a difference when you are not on the BTI payroll!  rate and reply
@ the Bell: Markets give up some recent gains
After the biggest two-day surge since 2020, North American markets gave up some ground on Wednesday. Canada’s main stock index retreated as the recent hot market rally was doused. Only the energy... read article.

Ayurcann Holdings expands product offerings across Canada

“We are thrilled with the growth of Ayurcann and its products within the Canadian marketplace. With the ability to produce products that are embraced by cannabis consumers, offering value and innovation, we are optimistic about our future growth and the potential of becoming an industry leader. We have been successfully selling throughout various Provinces within Canada, including Ontario, British Columbia, Alberta, New Brunswick, Manitoba, and Saskatchewan" - CEO Igal Sudman ...read more

RE:RE:RE:RE:A Little STFU Story

I certainly hate seeing the Bioasis management and BoD being publicly given permission to take the easy way out. They now have 13¢ options, a far cry from the $2 shares bought by many...read more

RE:RE:RE:A Little STFU Story

As I've said before, instead of the Phase II and the NASDAQ listing, I would much rather just wait it out until a partner starts a clinical trial, or just put the company up for sale: $2 US; $1 US...read more

RE:RE:A Little STFU Story

I agree with KayakerBC although I do see the possibility of an AGM/Special Meeting information circular and agenda coming out with no news beforehand and with a request for shareholder approval for a...read more

RE:A Little STFU Story

I think there is a good chance Bioasis will eventually be successful and worth big bucks.  The big question is whether existing shareholders will get through the start of the Phase II trial and...read more

A Little STFU Story

Endpoints News reported on Monday morning, October 3, 2022, that the tiny gene therapy company, LogicBio (LOGC-Q), was being acquired by AstraZeneca through its wholly-owned subsidiary, Alexion...read more
@ the Bell: Markets reclaim lost ground
Another session of broad gains helped power Canada’s main stock index to another solid close higher on Tuesday. Markets have regained some of their recent losses.Sponsored by ... read article.

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Prothena and Management's Reporting

With BTI burning money. Oxyrayne burning money. Aposense burning money.   rate and reply

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Prothena and Management's Reporting

My 2 cents,,,any PhDs I had an oprtunity to work with over the past years were sincere and interesting people,,,and I grew up beside one,,we have a load of these highly educated people involved and...read more

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Prothena and Management's Reporting

Lol. Puleeeeeeeze?? Every single shareholder I talk to has expressed what I have posted here in the last 2 days. You can make excuses for Bioasis but these are real questions. But I have more that...read more

RE:RE:RE:RE:RE:RE:RE:RE:RE:Prothena and Management's Reporting

It's simple. Bioasis can give guidance on the capabilities of xB3 and on whether and when it expects an IND submission to be made by anybody. Oh Geez, C'mon.  Bioasis should state it...read more

RE:RE:RE:RE:RE:RE:RE:RE:Prothena and Management's Reporting

KBC, no milestone has ever been reported reached. At the very least, with all the relationships past and present, Bioasis should at least report on xB3 and whether any relationship "faded"...read more

RE:RE:RE:RE:RE:RE:RE:Prothena and Management's Reporting

Give us your take on Prothena. Does xB3 work well enough to do business? Why are the deals so small? You can suggest whatever you want about my motives but it doesn't change the state that...read more

RE:RE:RE:RE:RE:RE:RE:Prothena and Management's Reporting

Here's a question for you. Has any licensee or partner ever made a milestone payment? Which prompts the question, has any partner or licensee ever reached a milestone? Chiesi, in over two years...read more

RE:RE:RE:RE:RE:RE:Prothena and Management's Reporting

My objectivity? Give us your take on Prothena. Does xB3 work well enough to do business? Why are the deals so small? You can suggest whatever you want about my motives but it doesn't change...read more

RE:RE:RE:RE:RE:Prothena and Management's Reporting

Meanwhile, if Bioasis is not fully reporting material events, circumstances and technology limitations, and is using language that purposefully obscures the status of Bioasis and xB3, would regulators...read more

RE:RE:RE:RE:Prothena and Management's Reporting

Let me explain it a little differently, G1945V.   Prothena allowed its options for two more xB3 targets to expire. (We'll just ignore the fact that the original deal was for three option...read more

RE:RE:RE:Prothena and Management's Reporting

"In my opinion, Bioasis is getting dangerously close to being a company that regulators might want to investigate." JD, ... What's this all about?        ...read more

RE:RE:Prothena and Management's Reporting

Agree, Sniper007, except that Bioasis does not mention any partners or licensees on its website, at all. The only references are contained in other media such as videos, presentations and in filings. ...read more

RE:Prothena and Management's Reporting

JD wrote: I consider it bad or lazy behaviour of Bioasis management to mischaracterize or otherwise obfuscate the status of the Bioasis/Prothena agreement. And that, of course, raises questions...read more

RE:Prothena and Management's Reporting

"Bioasis needs to clarify some stuff. If not then shareholders ought to get a leadership team in there that is capable or willing to do it." You can't wait and tell us after they'...read more